Literature DB >> 4177776

Genetic control of dicumarol levels in man.

E S Vesell, J G Page.   

Abstract

The mean half-life of dicumarol in the plasma of seven sets of identical and seven sets of fraternal twins after a single oral dose of 4 mg/kg was 43.6+/-SD 17.9 hr. Half-lives ranged from 7 to 74 hr in these 28 normal adults not receiving other drugs for 2 wk preceding dicumarol administration. Large differences among unrelated individuals in dicumarol half-life disappeared almost completely in identical twins, but persisted to some extent in most sets of fraternal twins. These results indicate that marked differences among subjects in dicumarol half-life are under genetic rather than environmental control. Reproducibility of values for dicumarol half-life was demonstrated. A direct relationship between the dose and the half-life of dicumarol occurred in unrelated volunteers administered progressively larger doses at 10-day intervals. Dose dependence of the half-life of a drug results in increased variability of half-life and hence in greater risks of toxicity on long-term therapy. Risks of toxicity on the one hand and of failure to anticoagulate adequately on the other can be reduced by determining dicumarol half-life before starting long-term therapy. Half-lives for dicumarol and phenylbutzone tended to be correlated in the 28 twins, but no correlation occurred between dicumarol and antipyrine half-lives.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4177776      PMCID: PMC297437          DOI: 10.1172/JCI105949

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  14 in total

Review 1.  MULTIFACTORIAL INHERITANCE AND HUMAN DISEASE.

Authors:  J A ROBERTS
Journal:  Prog Med Genet       Date:  1964

Review 2.  PHARMACOGENETICS.

Authors:  A G MOTULSKY
Journal:  Prog Med Genet       Date:  1964

3.  Hemorrhagic state due to surreptitious ingestion of bishydroxycoumarin. A detailed case study.

Authors:  R A O'REILLY; P M AGGELER; J O GIBBS
Journal:  N Engl J Med       Date:  1962-07-05       Impact factor: 91.245

4.  Dose-dependence of drug plasma level decline in dogs.

Authors:  P G Dayton; S A Cucinell; M Weiss; J M Perel
Journal:  J Pharmacol Exp Ther       Date:  1967-11       Impact factor: 4.030

5.  Pharmacological implications of microsomal enzyme induction.

Authors:  A H Conney
Journal:  Pharmacol Rev       Date:  1967-09       Impact factor: 25.468

6.  Genetic control of drug levels in man: antipyrine.

Authors:  E S Vesell; J G Page
Journal:  Science       Date:  1968-07-05       Impact factor: 47.728

7.  The effect of caffeine on drug metabolism.

Authors:  C Mitoma; T J Sorich; S E Neubauer
Journal:  Life Sci       Date:  1968-02-01       Impact factor: 5.037

8.  Stimulatory effect of nicotine on the metabolism of meprobamate.

Authors:  D G Wenzel; L L Broadie
Journal:  Toxicol Appl Pharmacol       Date:  1966-05       Impact factor: 4.219

9.  The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material.

Authors:  J J BURNS; R K ROSE; T CHENKIN; A GOLDMAN; A SCHULERT; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1953-11       Impact factor: 4.030

10.  Genetic control of drug levels in man: phenylbutazone.

Authors:  E S Vesell; J G Page
Journal:  Science       Date:  1968-03-29       Impact factor: 47.728

View more
  41 in total

Review 1.  Pharmacogenomics: challenges and opportunities.

Authors:  Dan M Roden; Russ B Altman; Neal L Benowitz; David A Flockhart; Kathleen M Giacomini; Julie A Johnson; Ronald M Krauss; Howard L McLeod; Mark J Ratain; Mary V Relling; Huijun Z Ring; Alan R Shuldiner; Richard M Weinshilboum; Scott T Weiss
Journal:  Ann Intern Med       Date:  2006-11-21       Impact factor: 25.391

2.  Anticoagulant effect and plasma kinetics of fluorophenindione after a single dose in man.

Authors:  J P Tillement; J J Thébault; C Mattei; P d'Athis; C Blatrix
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

3.  In Vitro-in Vivo Correlation: An Unrealistic Problem.

Authors:  R Hüttenrauch; P Speiser
Journal:  Pharm Res       Date:  1985-05       Impact factor: 4.200

4.  Development of a large-scale de-identified DNA biobank to enable personalized medicine.

Authors:  D M Roden; J M Pulley; M A Basford; G R Bernard; E W Clayton; J R Balser; D R Masys
Journal:  Clin Pharmacol Ther       Date:  2008-05-21       Impact factor: 6.875

5.  Individual variation in the response to phenprocoumon.

Authors:  S Husted; F Andreasen
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

6.  Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.

Authors:  E S Vesell; J G Page
Journal:  J Clin Invest       Date:  1969-12       Impact factor: 14.808

Review 7.  Systems biology and functional genomics approaches for the identification of cellular responses to drug toxicity.

Authors:  Alison Hege Harrill; Ivan Rusyn
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-11       Impact factor: 4.481

8.  Liver function in physically trained subjects: galactose elimination capacity, plasma disappearance of indocyanine green, and aminopyrine metabolism in long-distance runners.

Authors:  J J Ducry; H Howald; T Zysset; J Bircher
Journal:  Dig Dis Sci       Date:  1979-03       Impact factor: 3.199

9.  Comparison of single dose kinetics of imipramine, nortriptyline and antipyrine in man.

Authors:  L F Gram; P B Andreasen; K F Overo; J Christiansen
Journal:  Psychopharmacology (Berl)       Date:  1976-10-20       Impact factor: 4.530

Review 10.  Drug interactions and clinical pharmacokinetics.

Authors:  M B Kristensen
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.